Skip to main page content
Accesskeys
Review
Drug Des Devel Ther, 11, 881-891

Delafloxacin: Design, Development and Potential Place in Therapy

Review

Delafloxacin: Design, Development and Potential Place in Therapy

Francisco Javier Candel et al. Drug Des Devel Ther.

Abstract

Delafloxacin (DLX) is a new fluoroquinolone pending approval, which has shown a good in vitro and in vivo activity against major pathogens associated with skin and soft tissue infections and community-acquired respiratory tract infections. DLX also shows good activity against a broad spectrum of microorganisms, including those resistant to other fluoroquinolones, as methicillin-resistant Staphylococcus aureus. Its pharmacokinetic properties and excellent activity in acidic environments make DLX an alternative in the treatment of these and other infections. In this manuscript, a detailed analysis of this new fluoroquinolone is performed, from its chemical structure to its in vivo activity in recently published clinical trials. Its possible place in the current antimicrobial outlook and in other infectious models is also discussed.

Keywords: Delafloxacin; fluoroquinolones; methicillin-resistant Staphylococcus aureus; therapy.

Conflict of interest statement

Disclosure The authors declare no conflicts of interest in this work and have not received financial support.

Figures

Figure 1
Figure 1
Chemical structure of DLX compared with other quinolones (LVX, CPX, MXL).
Note: As DLX lacks a protonable substituent group in position 7, it is more acidic than other quinolones.
Abbreviations: CPX, ciprofloxacin; LVX, levofloxacin; MXL, moxifloxacin.
Figure 2
Figure 2
Predominant form of DLX (top) and MXL (bottom) at acidic and neutral pH.
Notes: The absence of a basic group in C7 allows DLX to be neutral at acidic pH and anionic at physiological pH. The opposite happens with MXL.
Abbreviations: DLX, delafloxacin; MXL, moxifloxacin.

Similar articles

Cited by 7 PubMed Central articles

References

    1. Hatoum HT, Akhras KS, Lin SJ. The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis. 2009;64(3):305–310. - PubMed
    1. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36(5):592–598. - PubMed
    1. Itani KMF, Merchant S, Lin SJ, Akhras K, Alandete JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control. 2011;39(1):42–49. - PubMed
    1. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15(9):1516–1518. - PMC - PubMed
    1. Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin Proc. 2014;89(10):1436–1451. - PubMed

Publication types

Citation text
Download .RIS
Send To
Feedback